Latest news for Sirona Biochem (OTC:SRBCF) Stock

Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. The company has a business presence in Canada and France.

News

Guidance

Contracts

Management

Global

SRBCF

Sirona Biochem Hires Investor Relations Firm Consulting to Increase Awareness in US

SIRONA BIOCHEM CORP ORD by Sirona Biochem Corp.

Sirona Biochem Corp

Press Releases

Sirona Biochem Initiates Private Placement

Financing

Sirona Biochem Announces Loan

Sirona Biochem Engages Global Beauty Consulting

Sirona Biochem Provides Update on Loan

General

Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Announces 2023 Annual Meeting Results

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Engages Stonegate Healthcare Partners

Health Care

Analyst Ratings

GlycoProteMim Featured in Stonegate Healthcare's Latest Anti-Aging Research Report

TSXV:SBM

Sirona Biochem

VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) --&nbsp;<a href="https://www.globenewswire.com/Tracker?data=SSnItRFFgQW68eRdMqUURGOrY6T6D9A4_nsmUcBsoYpQ2JDFEKrwadxeC1DoDEhVkh8y-JeC4CI_D856lCI_Acxo3qLBe9DwVTHoJMUe6cg=" target="_blank">Sirona Biochem Corp</a>. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/SBM#TSXV">SBM</a>) (FSE: ZSB) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SRBCF#OTC">SRBCF</a>) (&quot;Sirona&quot;) is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona&#39;s patents for&nbsp;<a href="https://www.globenewswire.com/Tracker?data=qsiAlBZqsQgyb31BJcRcVSpPqdsJ1qchVbduBqSWvPadgrxXy_mHimxw6f5o7dGb5nY_z-s8SwHbk4UKAVIYeIUDzdmoAr9fpC4F5lGQNPQ=" target="_blank">TFC-1067</a>&nbsp;and related family of compounds. 
&nbsp;

Biotech

ABBV

Allergan To Develop And Commercialize Topical Skin Care Treatments Based On Active Ingredients Derived From Certain Of Sirona's Patents For TFC-1067 And Related Family Of Compounds

Sirona Biochem (OTC: <a class="ticker" href="/stock/srbcf#OTC">SRBCF</a>) announced today it has hired Consulting for Strategic Growth 1 (CFSG1), an investor relations and corporate development firm based in New York City. CFSG1 has been hired to increase awareness of Sirona Biochem in the U.S. marketplace. "Now that we are trading on the OTCQX in the U.S., it's important to have strong, credible U.S. representation to communicate the value of Sirona Biochem and the excellent progress we have been making," said Neil Belenkie, Sirona Biochem Chief Executive Officer. "CFSG1 has proven expertise in taking emerging growth companies to the forefront of the American investor marketplace and we look forward to working with their team to share Sirona Biochem's story."Stan Wunderlich, Chairman and CEO of CFSG1, commented, "Sirona Biochem is changing the nature of carbohydrate-based chemistry and is delivering new, powerful compounds that have the potential to change the landscape of the drug, cosmetic and biochemistry industries. We are excited to be a partner in this venture and believe a great opportunity exists for this company in the public arena."Sirona Biochem will pay CFSG1 US$8,750.00 per month during a six month term starting February 1, 2013 and,
 
 <a href="http://www.benzinga.com/pressreleases/13/01/m3261082/sirona-biochem-hires-new-york-based-investor-relations-firm-consulting-">See full press release</a>

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Sirona Biochem

News

Latest news for Sirona Biochem (OTC:SRBCF) Stock

Monday, June 13, 2022

Tuesday, January 22, 2013